Diagnology files to market herpes test in US
This article was originally published in Clinica
Diagnology has filed for clearance to market its rapid point-of-care test for the herpes simplex virus, HSV 2, in the US. The POCkit test, an immunoassay, identifies patients infected with genital herpes by detecting HSV 2 specific antibodies in their blood, regardless of whether symptoms are present or not. The test, which can produce results in under 10 minutes, is already available in Europe, said the Belfast-based company.
You may also be interested in...
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.
Baxter has recalled more than half a million infusion pumps due to concerns improper cleaning could cause their batteries to malfunction. The recall was designated as high-risk class I by the US FDA.